ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.508,67
1,09%
S&P 500
5.127,79
1,26%
US Dollar vs BRL
5,0724
0,00%
Bitcoin
64.112,06
0,34%
Brent Oil
82,765
0,00%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Lipocine Inc (LPCN)

  7. Lipocine Inc (LPCN) Notícias

LPCN

Lipocine (LPCN)

Lipocine Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:LPCN
DataHoraFonteTítuloCódigoCompanhia
01/05/202409:00PR Newswire (US)Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154NASDAQ:LPCNLipocine Inc
11/04/202408:00PR Newswire (US)Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with ObesityNASDAQ:LPCNLipocine Inc
28/03/202409:00PR Newswire (US)Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with CirrhosisNASDAQ:LPCNLipocine Inc
25/03/202409:00PR Newswire (US)Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154NASDAQ:LPCNLipocine Inc
07/03/202419:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
07/03/202410:00PR Newswire (US)Lipocine Announces Financial Results for the Full Year Ended December 31, 2023NASDAQ:LPCNLipocine Inc
07/03/202408:07Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:LPCNLipocine Inc
06/03/202410:00PR Newswire (US)Lipocine to Present at 36th Annual Roth ConferenceNASDAQ:LPCNLipocine Inc
06/02/202410:00PR Newswire (US)Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154NASDAQ:LPCNLipocine Inc
02/02/202410:00PR Newswire (US)Lipocine Announces Continued Commercialization of TLANDO® through Verity PharmaceuticalsNASDAQ:LPCNLipocine Inc
18/01/202410:00PR Newswire (US)Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and CanadaNASDAQ:LPCNLipocine Inc
19/12/202310:00PR Newswire (US)Lipocine to Present at Biotech Showcase 2024NASDAQ:LPCNLipocine Inc
22/11/202318:15Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:LPCNLipocine Inc
13/11/202316:45PR Newswire (US)Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023NASDAQ:LPCNLipocine Inc
08/11/202315:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LPCNLipocine Inc
08/11/202310:00PR Newswire (US)Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023NASDAQ:LPCNLipocine Inc
01/11/202309:00PR Newswire (US)Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting® 2023NASDAQ:LPCNLipocine Inc
26/10/202309:00PR Newswire (US)Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum DepressionNASDAQ:LPCNLipocine Inc
23/10/202320:00PR Newswire (US)Lipocine to Present at the H.C. Wainwright Annual NASH Investor ConferenceNASDAQ:LPCNLipocine Inc
19/09/202317:05PR Newswire (US)Lipocine to Present at the Cantor Fitzgerald Global Healthcare ConferenceNASDAQ:LPCNLipocine Inc
10/08/202309:00PR Newswire (US)Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023NASDAQ:LPCNLipocine Inc
27/07/202307:30PR Newswire (US)LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with CirrhosisNASDAQ:LPCNLipocine Inc
26/06/202310:21Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LPCNLipocine Inc
14/06/202309:00PR Newswire (US)Lipocine to Present at H.C. Wainwright Annual Neuropsychiatry Virtual ConferenceNASDAQ:LPCNLipocine Inc
07/06/202309:00PR Newswire (US)Lipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023NASDAQ:LPCNLipocine Inc
25/05/202316:11Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LPCNLipocine Inc
16/05/202308:00PR Newswire (US)Positive Topline Clinical Results Support Streamlined Development Pathway for LPCN 1154, Lipocine's Oral Candidate for Rapid Relief of DepressionNASDAQ:LPCNLipocine Inc
11/05/202307:00PR Newswire (US)Lipocine Announces Financial Results for the First Quarter Ended March 31, 2023NASDAQ:LPCNLipocine Inc
03/04/202317:06Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:LPCNLipocine Inc
03/04/202309:00PR Newswire (US)First Subject Dosed in the Clinical Bridge Study with Lipocine Depression Candidate, LPCN 1154NASDAQ:LPCNLipocine Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:LPCN

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
GOLL4
GOL PN
BOV
BHIA3
Grupo Casas Bahia ON
BOV
AZEV4
AZEVEDO PN
BOV
AZUL4
AZUL PN
BOV
PRIO3
PETRORIO ON
BOV
HETA4
HERCULES PN
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados